Drugs / d-alpha tocopherol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04134091 | Aug 2019 → Jun 2021 | metabolic dysfunction-associated steatohepatitis | Lipocine Inc. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | d-alpha tocopherol | “Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as 225 mg testosterone undecanoate + 238 mg...” NCT04134091 ↗ |
| Route | Oral | “Oral LPCN 1144 + d-alpha tocopherol” NCT04134091 ↗ |